Deepak V. Almeida

发表

Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal

Thomas Abeel, Qiandong Zeng, Bruce W. Birren, 2015, PLoS medicine.

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

Thomas Abeel, Abigail L Manson, Ashlee M Earl, 2016, Nature Genetics.

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

W. Bishai, Shashank Gupta, S. Tyagi, 2013, American journal of respiratory and critical care medicine.

The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Murugesan V. S. Rajaram, Michele A. Miller, Matthew Z. Anderson, 2020, Tuberculosis.

Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules.

T. Ndung’u, W. Bishai, D. Moody, 2015, The Journal of infectious diseases.

Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

J. Grosset, S. Tyagi, D. Almeida, 2008, Antimicrobial Agents and Chemotherapy.

Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection

J. Grosset, P. Converse, D. Almeida, 2010, Antimicrobial Agents and Chemotherapy.

Targeting DnaN for tuberculosis therapy using novel griselimycins

H. Matter, D. Heinz, R. Müller, 2015, Science.

Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against Mycobacterium tuberculosis

N. Fotouhi, J. Bibby, G. Aljayyoussi, 2023, ACS infectious diseases.

Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model

P. Converse, S. Tyagi, D. Almeida, 2020, Antimicrobial Agents and Chemotherapy.

Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations

J. Grosset, P. Converse, S. Tyagi, 2015, Antimicrobial Agents and Chemotherapy.

Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

P. Karakousis, J. Grosset, K. Mdluli, 2012, Antimicrobial Agents and Chemotherapy.

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

N. Fotouhi, P. Converse, K. Mdluli, 2019, Antimicrobial Agents and Chemotherapy.

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

J. Grosset, P. Converse, S. Tyagi, 2015, Proceedings of the National Academy of Sciences.

Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

J. Grosset, D. Almeida, E. Nuermberger, 2008, American journal of respiratory and critical care medicine.

Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of Tuberculosis

W. Bishai, J. Grosset, C. Peloquin, 2006, Antimicrobial Agents and Chemotherapy.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis

R. Chaisson, V. Saini, J. Grosset, 2018, Antimicrobial Agents and Chemotherapy.

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice

K. Dooley, J. Grosset, P. Converse, 2011, PLoS neglected tropical diseases.

Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection

J. Grosset, J. Alffenaar, T. S. van der Werf, 2010, Antimicrobial Agents and Chemotherapy.

Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo

J. Grosset, B. Ngcobo, D. Almeida, 2017, The Journal of antimicrobial chemotherapy.

Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis

D. Almeida, E. Nuermberger, C. Peloquin, 2017, Antimicrobial Agents and Chemotherapy.

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

W. Bishai, J. Grosset, P. Converse, 2013, American journal of respiratory and critical care medicine.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer

V. Saini, M. Rudek, Nicole M. Anders, 2018, PLoS neglected tropical diseases.

Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy

J. Grosset, B. Ngcobo, D. Almeida, 2016, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Pharmacodynamics of Clofazimine in a Mouse Model of Tuberculosis

J. Grosset, B. Ngcobo, D. Almeida, 2015, Antimicrobial Agents and Chemotherapy.

Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis

J. Grosset, S. Tyagi, D. Almeida, 2009, Antimicrobial Agents and Chemotherapy.

Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering

S. Beatson, C. Jackson, C. Greening, 2020, PLoS pathogens.

The evolution of nitroimidazole antibiotic resistance in Mycobacterium tuberculosis

S. Beatson, C. Jackson, C. Greening, 2019, bioRxiv.

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

Koen Andries, Thomas Ioerger, J. Sacchettini, 2016, Antimicrobial Agents and Chemotherapy.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer

J. Grosset, P. Converse, D. Almeida, 2018, Antimicrobial Agents and Chemotherapy.

Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa

Q. Zeng, B. Birren, A. McGuire, 2015 .

In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis

W. Bishai, J. Grosset, S. Tyagi, 2007, Antimicrobial Agents and Chemotherapy.

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

W. Jacobs, J. Grosset, S. Tyagi, 2012, The Indian journal of medical research.

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice

W. Bishai, J. Grosset, A. Pym, 2014, Mycobacterial diseases : tuberculosis & leprosy.

The Many Hosts of Mycobacteria 9 (MHM9): A conference report.

Murugesan V. S. Rajaram, Michele A. Miller, Matthew Z. Anderson, 2023, Tuberculosis.

Quantitative Analysis of the Phase Transition Mechanism Underpinning the Systemic Self-Assembly of a Mechanopharmaceutical Device

G. Rosania, K. Stringer, A. Willmer, 2021, Pharmaceutics.

An Adaptive Biosystems Engineering Approach towards Modeling the Soluble-to-Insoluble Phase Transition of Clofazimine

G. Rosania, K. Stringer, A. Willmer, 2021, Pharmaceutics.

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance

B. Birren, J. Wortman, A. Earl, 2016, Nature Genetics.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide

W. Bishai, S. Swindells, U. Lalloo, 2012, Proceedings of the National Academy of Sciences.